4
Changes in Ownership
Propanc Biopharma, Inc. Filed Acc 0001144204-15-001926
Chief Executive Officer sold 330,500 shares at an average $0.18 ($60,083)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Nathanielsz James Andrew Chief Executive Officer | 2012-09-04 | Sale | −250,000 | $0.20 | $50,000 | 9,782,261 | I |
| Nathanielsz James Andrew Chief Executive Officer | 2012-09-14 | Sale | −5,000 | $0.20 | $1,000 | 9,777,261 | I |
| Nathanielsz James Andrew Chief Executive Officer | 2012-12-13 | Sale | −5,500 | $0.20 | $1,100 | 9,771,761 | I |
| Nathanielsz James Andrew Chief Executive Officer | 2013-01-23 | Sale | −15,000 | $0.20 | $3,000 | 9,756,761 | I |
| Nathanielsz James Andrew Chief Executive Officer | 2013-07-05 | Sale | −55,000 | $0.09 | $4,983 | 9,701,761 | I |
| Derivatives | |||||||
| Nathanielsz James Andrew Chief Executive Officer | 2014-11-09 | Grant or award · Series A Preferred Stock | +500,000 | 500,000 | D | ||
| Open-market sales · 330,500 sh · avg $0.18 · $60,083 | |||||||
Loading xslF345X03/v396995_4.xml…